» Articles » PMID: 37525872

Review and Application of Integrin Alpha V Beta 6 in the Diagnosis and Treatment of Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Integrin Alpha v Beta 6 is expressed primarily in solid epithelial tumors, such as cholangiocarcinoma, pancreatic cancer, and colorectal cancer. It has been considered a potential and promising molecular marker for the early diagnosis and treatment of cancer. Cholangiocarcinoma and pancreatic ductal adenocarcinoma share genetic, histological, and pathophysiological similarities due to the shared embryonic origin of the bile duct and pancreas. These cancers share numerous clinicopathological characteristics, including growth pattern, poor response to conventional radiotherapy and chemotherapy, and poor prognosis. This review focuses on the role of integrin Alpha v Beta 6 in cancer progression. It addition, it reviews how the marker can be used in molecular imaging and therapeutic targets. We propose further research explorations and questions that need to be addressed. We conclude that integrin Alpha v Beta 6 may serve as a potential biomarker for cancer disease progression and prognosis.

Citing Articles

Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy.

Dadgar N, Arunachalam A, Hong H, Phoon Y, Arpi-Palacios J, Uysal M Cancers (Basel). 2024; 16(18).

PMID: 39335203 PMC: 11429565. DOI: 10.3390/cancers16183232.


Intra-arterial PSMA injection using hepatic arterial infusion pump in intrahepatic cholangiocarcinoma: a proof-of-concept study.

Veenstra M, Vegt E, Segbers M, Franssen S, Groot Koerkamp B, Verburg F Eur Radiol Exp. 2024; 8(1):90.

PMID: 39090480 PMC: 11294287. DOI: 10.1186/s41747-024-00496-4.

References
1.
Miller T, Yang F, Wise C, Meng F, Priester S, Munshi M . Simvastatin stimulates apoptosis in cholangiocarcinoma by inhibition of Rac1 activity. Dig Liver Dis. 2011; 43(5):395-403. PMC: 3071437. DOI: 10.1016/j.dld.2011.01.010. View

2.
Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao F . Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016; 64(4):1178-88. DOI: 10.1002/hep.28744. View

3.
Halbrook C, Lyssiotis C, Pasca di Magliano M, Maitra A . Pancreatic cancer: Advances and challenges. Cell. 2023; 186(8):1729-1754. PMC: 10182830. DOI: 10.1016/j.cell.2023.02.014. View

4.
Nishigaki T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hara H . Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. Br J Cancer. 2020; 122(9):1333-1341. PMC: 7189381. DOI: 10.1038/s41416-020-0781-2. View

5.
Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M . Genomic spectra of biliary tract cancer. Nat Genet. 2015; 47(9):1003-10. DOI: 10.1038/ng.3375. View